Skip to main content
Fig. 8 | Skeletal Muscle

Fig. 8

From: ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments

Fig. 8

Effects of everolimus and CDD866 on time-to-progression. Time-to-progression expressed by percentage of event defined by interruption criteria (a); median days elapsed before reaching an interruption criterion (b), expressed by box and whiskers with min to max; & P < 0.05, && P < 0.01 versus CT-26 control; $ P < 0.05 versus CT-26 CDD866. Distribution by termination criterion (c) and breakdown of time-to-progression by body weight loss (d) and tumor volume (e)

Back to article page

Skeletal Muscle

ISSN: 2044-5040

Contact us